Last $6.94 USD
Change Today -0.45 / -6.09%
Volume 96.2K
CBRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

columbia laboratories inc (CBRX) Snapshot

Open
$7.41
Previous Close
$7.39
Day High
$7.88
Day Low
$6.86
52 Week High
02/26/15 - $7.99
52 Week Low
01/12/15 - $5.09
Market Cap
74.8M
Average Volume 10 Days
85.9K
EPS TTM
$0.45
Shares Outstanding
10.8M
EX-Date
--
P/E TM
15.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for COLUMBIA LABORATORIES INC (CBRX)

Related News

No related news articles were found.

columbia laboratories inc (CBRX) Related Businessweek News

No Related Businessweek News Found

columbia laboratories inc (CBRX) Details

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and analytical and consulting services to the pharmaceutical industry. It focuses on the sale of CRINONE, a progesterone gel to its marketing partner. The company has licensed CRINONE to Merck Serono S.A. outside the United States; and has sold the rights to CRINONE to Actavis, Inc. in the United States. Columbia Laboratories, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

77 Employees
Last Reported Date: 03/5/14
Founded in 1986

columbia laboratories inc (CBRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $340.0K
Director and Chief Executive Officer of Molec...
Total Annual Compensation: $86.0K
Compensation as of Fiscal Year 2013.

columbia laboratories inc (CBRX) Key Developments

Columbia Laboratories, Inc. to Initiate A Phase II Clinical Trial for Col-1077 in the Second Quarter of 2015

Columbia Laboratories Inc. plans to initiate a Phase II clinical trial for COL-1077, a lidocaine bioadhesive 10% gel, in women undergoing transvaginal pipelle-directed endometrial biopsy in the second quarter of 2015. This is following pre-Investigational New Drug (IND) submission feedback from the United States Food and Drug Administration (FDA). COL-1077 is being developed as a sustained-release lidocaine gel for vaginal administration, intended as an acute-use anesthetic during minimally invasive gynecologic procedures. Approximately five million gynecological procedures are performed in the U.S. annually, representing a significant need for a safe and effective localized pain treatment for women undergoing these procedures. The company expects to commence a Phase II clinical trial in the second quarter of 2015. This trial will be a multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of a single dose of COL-1077 in women undergoing transvaginal pipelle-directed endometrial biopsy. Clinical trial supplies for the Phase II trial will be produced at the company's Nottingham facility.

Columbia Laboratories Inc. Announces the Retirement of Stephen G. Kasnet as Chairman

Columbia Laboratories Inc. announced that the company's Chairman, Stephen G. Kasnet, has informed the company that he does not intend to stand for reelection to the Board of Directors when his current term expires at the next annual shareholder meeting, which is expected to be held in May, 2015.

Columbia Laboratories Inc. Approves Amendments to Articles of Incorporation

On January 9, 2015, the Board of Directors of Columbia Laboratories Inc. approved an amendment to Article I, Section 9 of the company’s Amended and Restated By-Laws to change the voting standard for uncontested elections of directors to a majority of votes cast from a plurality standard.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBRX:US $6.94 USD -0.45

CBRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.37 USD -0.24
View Industry Companies
 

Industry Analysis

CBRX

Industry Average

Valuation CBRX Industry Range
Price/Earnings 14.9x
Price/Sales 2.2x
Price/Book 1.8x
Price/Cash Flow 13.9x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLUMBIA LABORATORIES INC, please visit www.columbialabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.